Rekovelle Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing infertility rates, expansion of assisted reproductive technology clinics, rising maternal age trends, improved availability of fertility medications, clinical validation of recombinant hormone therapies.

The growth in the forecast period can be attributed to increasing demand for IVF procedures, growing preference for personalized fertility care, expansion of fertility tourism, rising investment in reproductive health services, continued innovation in hormonal stimulation therapies. Major trends in the forecast period include increasing adoption of personalized fertility treatments, rising use of recombinant gonadotropins, growing focus on individualized ovarian stimulation protocols, expansion of ivf treatment volumes, enhanced precision in hormonal dosing.

The increasing prevalence of infertility is expected to drive the growth of the rekovelle market going forward. Infertility rates represent the share of couples or individuals within a given population who are unable to conceive after attempting for a specified period, typically one year, despite regular, unprotected sexual activity. The rising incidence of infertility is influenced by factors such as postponed parenthood, lifestyle modifications, exposure to environmental toxins, and underlying medical conditions, resulting in higher demand for fertility treatments. Rekovelle helps address infertility by enhancing ovarian response and improving the outcomes of assisted reproductive technologies such as IVF, thereby increasing the likelihood of successful fertilization and pregnancy. For instance, in April 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, around 17.5% of the global adult population, or approximately 1 in 6 people, experience infertility. Therefore, the increasing prevalence of infertility is driving the growth of the rekovelle market.

The rising prevalence of genetic conditions is expected to propel the growth of the rekovelle market going forward. Genetic conditions are disorders resulting from abnormalities in an individual’s DNA, including mutations, deletions, or duplications. The occurrence of genetic conditions is increasing due to factors such as advanced parental age, which elevates the risk of DNA mutations in eggs and sperm. Rekovelle supports individuals facing genetically related fertility challenges by stimulating ovarian follicle development to support effective IVF treatment. For instance, in March 2024, according to Gene People, a UK-based registered charity, genetic conditions affect an estimated 1 in 25 children, impacting more than 2.4 million children and adults across the UK. Therefore, the rising prevalence of genetic conditions is driving the growth of the rekovelle market.

Major companies operating in the rekovelle market are concentrating on the development of innovative approaches, such as personalized ovarian stimulation, to address the growing demand for more effective and safer fertility treatments. Personalized ovarian stimulation involves customizing treatment, including drug dosage, based on individual patient characteristics such as body weight and anti-Müllerian hormone levels, rather than applying a uniform dosage. In March 2023, Ferring Pharmaceuticals A/S, a Switzerland-based pharmaceutical company, presented findings from the PROFILE study, the first prospective, real-world study of Rekovelle (follitropin delta). The results indicated that approximately 74% of participants achieved retrieval of between 4 and 19 oocytes, and ongoing pregnancy rates were consistent with those reported in earlier Phase 3 trials. An individualized dosing algorithm based on body weight and AMH levels was applied in 95% of cases. These results reinforce Rekovelle’s effectiveness and safety in a real-world personalized ovarian stimulation setting.

Major companies operating in the rekovelle market are Ferring Pharmaceuticals A/S.

Europe was the largest region in the rekovelle market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rekovelle market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rekovelle market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the rekovelle market by increasing costs of imported recombinant hormones, biopharmaceutical manufacturing inputs, prefilled injection devices, and cold-chain distribution services. Fertility treatment centers in Europe and North America are most affected due to dependence on specialized imported drug substances, while Asia-Pacific experiences higher supply chain costs for fertility medications. These tariffs contribute to higher IVF treatment expenses and affordability challenges. At the same time, they are supporting regional biologics manufacturing, encouraging local fill-finish capabilities, and strengthening domestic supply chains for fertility drugs.

The rekovelle market research report is one of a series of new reports that provides rekovelle market statistics, including rekovelle industry global market size, regional shares, competitors with a rekovelle market share, detailed rekovelle market segments, market trends and opportunities, and any further data you may need to thrive in the rekovelle industry. This rekovelle market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rekovelle is a fertility medication that contains the recombinant hormone follitropin delta and is used to stimulate the development of ovarian follicles in women undergoing in vitro fertilization (IVF). It supports the production of multiple eggs, thereby improving the chances of successful fertilization and pregnancy.

The key indications for Rekovelle include controlled ovarian stimulation and polycystic ovary syndrome. Controlled ovarian stimulation (COS) is a fertility treatment in which hormones are administered to encourage the ovaries to produce multiple eggs for fertilization, most commonly as part of in vitro fertilization (IVF). The medication is distributed through various channels, including hospitals, clinics, and pharmacies, and is intended for a range of end users such as pediatric, adult, and geriatric populations.

The rekovelle market consists of sales of products including injections, pre-filled syringes, vials, and dose adjuster kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.